Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All zinc studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2

Bess et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1297924
Dec 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Zinc for COVID-19
2nd treatment shown to reduce risk in July 2020
 
*, now known with p = 0.0000027 from 43 studies, recognized in 10 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
In Silico study showing potential benefit of zinc against SARS-CoV-2 according to an AI platform, eVir, designed to identify repurposed oral therapies. The software pipeline analyzes drug impacts on protein-protein networks involved in viral entry, fusion, and replication. Zinc obtained the one of the highest similarity scores to known antiviral peptides, suggesting significant potential as an oral therapeutic based on its pharmacological profile.
Bess et al., 22 Dec 2023, peer-reviewed, 7 authors. Contact: bess@deepdrug.ai.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperZincAll
Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2
Adam Bess, Frej Berglind, Supratik Mukhopadhyay, Michal Brylinski, Chris Alvin, Fanan Fattah, Kishor M Wasan
Frontiers in Pharmacology, doi:10.3389/fphar.2023.1297924
Purpose: This study introduces a sophisticated computational pipeline, eVir, designed for the discovery of antiviral drugs based on their interactions within the human protein network. There is a pressing need for cost-effective therapeutics for infectious diseases (e.g., , particularly in resourcelimited countries. Therefore, our team devised an Artificial Intelligence (AI) system to explore repurposing opportunities for currently used oral therapies. The eVir system operates by identifying pharmaceutical compounds that mirror the effects of antiviral peptides (AVPs)-fragments of human proteins known to interfere with fundamental phases of the viral life cycle: entry, fusion, and replication. eVir extrapolates the probable antiviral efficacy of a given compound by analyzing its established and predicted impacts on the human protein-protein interaction network. This innovative approach provides a promising platform for drug repurposing against SARS-CoV-2 or any virus for which peptide data is available. Methods: The eVir AI software pipeline processes drug-protein and proteinprotein interaction networks generated from open-source datasets. eVir uses Node2Vec, a graph embedding technique, to understand the nuanced connections among drugs and proteins. The embeddings are input a Siamese Network (SNet) and MLPs, each tailored for the specific mechanisms of entry, fusion, and replication, to evaluate the similarity between drugs and AVPs. Scores generated from the SNet and MLPs undergo a Platt probability calibration and are combined into a unified score that gauges the potential antiviral efficacy of a drug. This integrated approach seeks to boost drug identification confidence, offering a potential solution for detecting therapeutic candidates with pronounced antiviral potency. Once identified a number of compounds were tested for efficacy and toxicity in lung carcinoma cells (Calu-3) infected with SARS-CoV-2. A lead compound was further identified to determine its efficacy and toxicity in K18-hACE2 mice infected with SARS-CoV-2. Computational Predictions: The SNet confidently differentiated between similar and dissimilar drug pairs with an accuracy of 97.28% and AUC of 99.47%.
Ethics statement Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. The animal study was approved by This animal work was done at IITRI CRO which has appropriate ethics approval. The study was conducted in accordance with the local legislation and institutional requirements. Author contributions Conflict of interest Author KW has stock options in Skymount Medical. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abou Dalle, Kantarjian, Burger, Estrov, Ohanian et al., Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States, Cancer Med, doi:10.1002/cam4.2545
Agarwal, Gabrani, Antiviral peptides: identification and validation, Int. J. Peptide Res. Ther, doi:10.1007/s10989-020-10072-0
Amidei, Dobrovolny, Estimation of virus-mediated cell fusion rate of SARS-CoV-2, Virology, doi:10.1016/j.virol.2022.08.016
Ariey-Bonnet, Carrasco, Le Grand, Hoffer, Betzi et al., In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor, Mol. Oncol, doi:10.1002/1878-0261.12810
Assaad, Assaad-Khalil, Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS-COV-2 induced pneumonia, Alexandria J. Med, doi:10.1080/20905068.2020.1778417
Bess, Berglind, Mukhopadhyay, Brylinski, Griggs et al., Artificial intelligence for the discovery of novel antimicrobial agents for emerging infectious diseases, Drug Discov. Today, doi:10.1016/j.drudis.2021.10.022
Bess, None
Bess, None
Bess, None
Bouhaddou, Memon, Meyer, White, Rezelj et al., The global phosphorylation landscape of SARS-CoV-2 infection, Cell, doi:10.1016/j.cell.2020.06.034
Bromley, Bentz, Bottou, Guyon, Lecun et al., Signature verification using a "siamese" time delay neural network, doi:10.1142/s0218001493000339
Dalziel, Round, Garside, Stein, Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia, Pharmacoeconomics, doi:10.2165/00019053-200523050-00010
Dittmar, Lee, Whig, Segrist, Li et al., Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2, Cell Rep, doi:10.1016/j.celrep.2021.108959
Drew, Wallingford, Marcotte, MAP 2.0: integration of over 15,000 proteomic experiments builds a global compendium of human multiprotein assemblies, Mol. Syst. Biol, doi:10.15252/msb.202010016
Gancheva, Virchis, Howard-Reeves, Cross, Brazma et al., Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review, Mol. Cytogenet, doi:10.1186/1755-8166-6-39
García, Cooper, Shi, Bornmann, Carrion et al., Productive replication of ebola virus is regulated by the c-Abl1 tyrosine kinase, Sci. Transl. Med, doi:10.1126/scitranslmed.3003500
Gargouri, Alzwi, Abobaker, Cyclin dependent kinase inhibitors as a new potential therapeutic option in management of COVID-19, Med. Hypotheses, doi:10.1016/j.mehy.2020.110380
Gassen, Papies, Bajaj, Emanuel, Dethloff et al., SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals, Nat. Commun, doi:10.1038/s41467-021-24007-w
Gilson, Liu, Baitaluk, Nicola, Hwang et al., BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology, Nucleic Acids Res, doi:10.1093/nar/gkv1072
Giurgiu, Reinhard, Brauner, Dunger-Kaltenbach, Fobo et al., CORUM: the comprehensive resource of mammalian protein complexes-2019, Nucleic Acids Res, doi:10.1093/nar/gky973
Grover, Leskovec, Node2vec: scalable feature learning for networks
Hancock, Haney, Gill, The immunology of host defence peptides: beyond antimicrobial activity, Nat. Rev. Immunol, doi:10.1038/nri.2016.29
Kantarjian, Larson, Guilhot, O'brien, Mone et al., Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase, Cancer, doi:10.1002/cncr.24066
Klann, Bojkova, Tascher, Ciesek, Münch et al., Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication, Mol. Cell, doi:10.1016/j.molcel.2020.08.006
Koch, Siamese neural networks for one-shot image recognition
Kuhlmann, Fleckenstein, Antiparasitic agents, Infectious diseases
Lazebnik, Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects, Oncotarget, doi:10.18632/oncotarget.28088
Liu, Lin, Wen, Jorissen, Gilson, BindingDB: a webaccessible database of experimentally determined protein-ligand binding affinities, Nucleic Acids Res, doi:10.1093/nar/gkl999
Liu, Naderi, Alvin, Mukhopadhyay, Brylinski, Break down in order to build up: decomposing small molecules for fragment-based drug design with eMolFrag, J. Chem. Inf. Model, doi:10.1021/acs.jcim.6b00596
Maxwell, Sanders, Sabot, Hachem, Llanos-Cuentas et al., COVID-19 therapeutics for low-and middle-income countries: a review of candidate agents with potential for near-term use and impact, Am. J. Trop. Med. Hyg, doi:10.4269/ajtmh.21-0200
Mering, Huynen, Jaeggi, Schmidt, Bork et al., STRING: a database of predicted functional associations between proteins, Nucleic Acids Res, doi:10.1093/nar/gkg034
Mikolov, Chen, Corrado, Dean, Efficient estimation of Word representations in vector space
Mikolov, Sutskever, Chen, Corrado, Dean, Distributed representations of words and phrases and their compositionality
Naderi, Alvin, Ding, Mukhopadhyay, Brylinski, A graphbased approach to construct target-focused libraries for virtual screening, J. Cheminform, doi:10.1186/s13321-016-0126-6
Niculescu-Mizil, Caruana, Obtaining calibrated probabilities from boosting
Niculescu-Mizil, Caruana, Predicting good probabilities with supervised learning
Peng, Lloyd, Schran, Clinical pharmacokinetics of imatinib, Clin. Pharmacokinet, doi:10.2165/00003088-200544090-00001
Pickard, Calverley, Chang, Garva, Gago et al., Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells, PLoS Pathog, doi:10.1371/journal.ppat.1009840
Pu, Naderi, Liu, Wu, Mukhopadhyay et al., eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates, BMC Pharmacol. Toxicol, doi:10.1186/s40360-018-0282-6
Qureshi, Thakur, Kumar, HIPdb: a database of experimentally validated HIV inhibiting peptides, PLoS One, doi:10.1371/journal.pone.0054908
Qureshi, Thakur, Tandon, Kumar, AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses, Nucleic Acids Res, doi:10.1093/nar/gkt1191
Reeves, Smith, Olson, Thorne, Bornmann et al., Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and Src family tyrosine kinases, J. Virol, doi:10.1128/jvi.01814-10
Sasaki, Ramesh, Chada, Gomyo, Roth et al., The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells, Mol. Cancer Ther
Shcherbakov, Ei, Firsova, The mebendazole treatment of patients with alveolar echinococcosis, Med. Parazitol. Mosk
Simbulan-Rosenthal, Dakshanamurthy, Gaur, Chen, Fang et al., The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma, Oncotarget, doi:10.18632/oncotarget.14990
Snel, Lehmann, Bork, Huynen, STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene, Nucleic Acids Res, doi:10.1093/nar/28.18.3442
Szklarczyk, Gable, Lyon, Junge, Wyder et al., STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets, Nucleic Acids Res, doi:10.1093/nar/gky1131
Szklarczyk, Kirsch, Koutrouli, Nastou, Mehryary et al., The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest, Nucleic Acids Res, doi:10.1093/nar/gkac1000
Talarico, Pignatti, Pazdur, Registration by the European Agency for the Evaluation of Medicinal products (EMEA) of oncology products approved by the Food and Drug Administration (FDA) under accelerated approval (AA) regulations, J. Clin. Oncol, doi:10.1200/jco.2005.23.16_suppl.6054
Wang, Yang, The therapeutic potential of natural dietary flavonoids against SARS-CoV-2 infection, Nutrients, doi:10.3390/nu15153443
Weston, Coleman, Haupt, Logue, Matthews et al., Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo, J. Virol, doi:10.1128/JVI.01218-20
Wishart, Feunang, Guo, Lo, Marcu et al., DrugBank 5.0: a major update to the DrugBank database for 2018, Nucleic Acids Res, doi:10.1093/nar/gkx1037
Wishart, Knox, Guo, Cheng, Shrivastava et al., DrugBank: a knowledgebase for drugs, drug actions and drug targets, Nucleic Acids Res, doi:10.1093/nar/gkm958
Wishart, Knox, Guo, Shrivastava, Hassanali et al., DrugBank: a comprehensive resource for in silico drug discovery and exploration, Nucleic Acids Res, doi:10.1093/nar/gkj067
Zhao, Mendenhall, Deininger, Imatinib is not a potent anti-SARS-CoV-2 drug, Leukemia, doi:10.1038/s41375-020-01045-9
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit